Superantigen post-exposure therapy

A pharmaceutical composition for use in the post-exposure treatment of superantigen (SAg)-mediated disease in a subject, wherein the pharmaceutical composition comprises an active ingredient which is capable of binding an antigen presenting cell B7 receptor. The active ingredient may be CTLA4Ig and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	ALUN JAMES CARTER, SARAH JOANNE CHRISTINE WHITFIELD
Format:	Patent
Sprache:	eng
Schlagworte:	HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS TESTING
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A pharmaceutical composition for use in the post-exposure treatment of superantigen (SAg)-mediated disease in a subject, wherein the pharmaceutical composition comprises an active ingredient which is capable of binding an antigen presenting cell B7 receptor. The active ingredient may be CTLA4Ig and the superantigen may be Staphylococcus Enterotoxin B (SEB). Also claimed is a method for monitoring responsiveness to post-exposure treatment of SAg-mediated disease with a pharmaceutical composition comprises an active ingredient which is capable of binding an antigen presenting cell B7 receptor comprising measuring the concentration of biomarkers IFN-Î³ or IL-6 in pre-treatment and post-treatment samples and wherein a biomarker concentration lower in the post-treatment sample is a positive indicator of responsiveness to treatment.